|
Neuland Laboratories Limited (Neulandlab.NS) Évaluation DCF
IN | Healthcare | Drug Manufacturers - Specialty & Generic | NSE
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Neuland Laboratories Limited (NEULANDLAB.NS) Bundle
Vous cherchez à déterminer la valeur intrinsèque de Neuland Laboratories Limited? Notre calculatrice DCF (NEULANDLABNS) intègre des données réelles avec des fonctionnalités de personnalisation étendues, vous permettant d'ajuster les prévisions et d'améliorer vos choix d'investissement.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,577.5 | 9,242.7 | 9,253.0 | 11,912.0 | 15,585.8 | 18,767.8 | 22,599.5 | 27,213.5 | 32,769.5 | 39,459.8 |
| Revenue Growth, % | 0 | 21.98 | 0.11228 | 28.74 | 30.84 | 20.42 | 20.42 | 20.42 | 20.42 | 20.42 |
| EBITDA | 1,057.8 | 1,629.1 | 1,447.0 | 2,815.9 | 4,748.2 | 3,803.4 | 4,579.9 | 5,515.0 | 6,640.9 | 7,996.7 |
| EBITDA, % | 13.96 | 17.63 | 15.64 | 23.64 | 30.46 | 20.27 | 20.27 | 20.27 | 20.27 | 20.27 |
| Depreciation | 312.8 | 396.8 | 490.4 | 527.8 | 597.0 | 825.1 | 993.6 | 1,196.4 | 1,440.7 | 1,734.8 |
| Depreciation, % | 4.13 | 4.29 | 5.3 | 4.43 | 3.83 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 |
| EBIT | 745.0 | 1,232.3 | 956.6 | 2,288.1 | 4,151.2 | 2,978.3 | 3,586.3 | 4,318.5 | 5,200.2 | 6,261.9 |
| EBIT, % | 9.83 | 13.33 | 10.34 | 19.21 | 26.63 | 15.87 | 15.87 | 15.87 | 15.87 | 15.87 |
| Total Cash | 283.1 | 105.5 | 84.7 | 661.3 | 1,025.9 | 672.9 | 810.2 | 975.7 | 1,174.9 | 1,414.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,920.0 | 2,206.6 | 2,379.6 | 3,687.1 | 3,759.9 | 4,879.9 | 5,876.2 | 7,075.9 | 8,520.5 | 10,260.1 |
| Account Receivables, % | 25.34 | 23.87 | 25.72 | 30.95 | 24.12 | 26 | 26 | 26 | 26 | 26 |
| Inventories | 2,195.5 | 2,476.1 | 2,652.1 | 2,792.3 | 3,504.2 | 4,892.8 | 5,891.7 | 7,094.6 | 8,543.0 | 10,287.2 |
| Inventories, % | 28.97 | 26.79 | 28.66 | 23.44 | 22.48 | 26.07 | 26.07 | 26.07 | 26.07 | 26.07 |
| Accounts Payable | 1,155.6 | 1,521.3 | 1,173.8 | 1,710.1 | 1,919.6 | 2,667.6 | 3,212.2 | 3,868.1 | 4,657.8 | 5,608.7 |
| Accounts Payable, % | 15.25 | 16.46 | 12.69 | 14.36 | 12.32 | 14.21 | 14.21 | 14.21 | 14.21 | 14.21 |
| Capital Expenditure | -488.0 | -1,054.0 | -958.8 | -661.3 | -1,436.7 | -1,613.1 | -1,942.4 | -2,339.0 | -2,816.5 | -3,391.5 |
| Capital Expenditure, % | -6.44 | -11.4 | -10.36 | -5.55 | -9.22 | -8.59 | -8.59 | -8.59 | -8.59 | -8.59 |
| Tax Rate, % | 25.25 | 25.25 | 25.25 | 25.25 | 25.25 | 25.25 | 25.25 | 25.25 | 25.25 | 25.25 |
| EBITAT | 228.2 | 943.3 | 743.0 | 1,734.2 | 3,103.1 | 1,997.8 | 2,405.7 | 2,896.9 | 3,488.3 | 4,200.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2,906.9 | 84.7 | -421.9 | 689.3 | 1,688.2 | -550.6 | 6.3 | 7.6 | 9.2 | 11.0 |
| WACC, % | 9.28 | 9.32 | 9.33 | 9.32 | 9.32 | 9.32 | 9.32 | 9.32 | 9.32 | 9.32 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -479.1 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 11 | |||||||||
| Terminal Value | 216 | |||||||||
| Present Terminal Value | 138 | |||||||||
| Enterprise Value | -341 | |||||||||
| Net Debt | 78 | |||||||||
| Equity Value | -419 | |||||||||
| Diluted Shares Outstanding, MM | 13 | |||||||||
| Equity Value Per Share | -32.67 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled financial data for Neuland Laboratories Limited (NEULANDLABNS).
- Accurate Data: Access to historical financial data and future projections (highlighted in the yellow cells).
- Flexible Forecasting: Modify key assumptions such as revenue growth, EBITDA %, and WACC as needed.
- Instant Calculations: Quickly assess how your input affects the valuation of Neuland Laboratories Limited (NEULANDLABNS).
- Professional Resource: Designed for use by investors, CFOs, consultants, and financial analysts alike.
- User-Friendly Interface: Organized for ease of understanding and navigation, complete with step-by-step guidance.
Key Features
- Customizable Forecast Variables: Adjust essential metrics such as revenue growth, EBITDA %, and capital expenditures.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other financial outputs.
- High-Precision Accuracy: Leverages Neuland Laboratories’ real financial data for credible valuation results.
- Simplified Scenario Analysis: Easily evaluate various assumptions and assess different outcomes.
- Efficiency-Boosting Tool: Remove the complexities of constructing intricate valuation models from the ground up.
How It Operates
- 1. Access the Template: Download and open the Excel file featuring Neuland Laboratories Limited’s preloaded data.
- 2. Adjust Assumptions: Modify key inputs such as growth rates, WACC, and capital expenditures as needed.
- 3. Immediate Results: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Scenarios: Evaluate different forecasts to assess various valuation outcomes.
- 5. Make Informed Decisions: Share professional valuation insights to enhance your decision-making process.
Why Choose This Calculator for Neuland Laboratories Limited (NEULANDLABNS)?
- Precision: Utilizes authentic Neuland financial data for reliable outcomes.
- Versatility: Built to allow users to easily adjust and experiment with their inputs.
- Efficiency: Avoid the complexity of creating a DCF model from the ground up.
- Expert-Level: Crafted with the accuracy and functionality expected by finance professionals.
- Intuitive: Simple enough for anyone, regardless of their financial modeling expertise.
Who Can Benefit from This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for analyzing portfolios involving Neuland Laboratories Limited (NEULANDLABNS).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Consultants and Advisors: Deliver precise valuation insights to clients focused on Neuland Laboratories Limited (NEULANDLABNS).
- Students and Educators: Utilize real-world data to enhance financial modeling skills and education.
- Pharmaceutical Enthusiasts: Gain insights into how pharmaceutical companies like Neuland Laboratories Limited (NEULANDLABNS) are assessed in the market.
Contents of the Template
- Historical Data: Provides an overview of Neuland Laboratories Limited’s past financial performance and initial forecasts.
- DCF and Levered DCF Models: Comprehensive templates designed to assess the intrinsic value of Neuland Laboratories Limited (NEULANDLABNS).
- WACC Sheet: Ready-to-use calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Customize key metrics such as growth rates, EBITDA percentages, and CAPEX projections.
- Quarterly and Annual Statements: A thorough analysis of Neuland Laboratories Limited’s financial statements.
- Interactive Dashboard: An engaging platform to visualize valuation outcomes and forecasts in real time.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.